Paper Details

  1. Home
  2. Paper Details

Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.

Author: , ClaarE, CoppolaN, De PascalisS, FraiaA Di, MessinaV, MinichiniC, OcchielloL, PisaturoM, SangiovanniV, StaraceM

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study characterized virological patterns in patients with failure to current direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection. The study found a high prevalence of NS5A resistance-associated substitutions in patients treated with sofosbuvir/velpatasvir and elbasvir/grazoprevir, while re-treatment with sofosbuvir/velpatasvir and voxilaprevir was highly effective.
Paper Details　
Original Abstract of the Article :
There are few data on the virological characterisation of patients with failure to current-generation direct-acting antivirals (DAAs), namely elbasvir/grazoprevir, sofosbuvir/velpatasvir and glecaprevir/pibrentasvir. This study aimed to characterise virological patterns in patients with failure to c...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ijantimicag.2020.106067

データ提供：米国国立医学図書館（NLM）

Virological Patterns in Hepatitis C Virus Patients with Failure to Direct-Acting Antivirals

This study delves into the complex world of hepatitis C virus (HCV) treatment, focusing on the virological characteristics of patients who fail to respond to current-generation direct-acting antivirals (DAAs), a highly effective class of medications for treating HCV infection. The researchers analyzed a cohort of 61 patients who experienced treatment failure with DAAs, identifying specific viral mutations, known as resistance-associated substitutions (RASs), in the HCV genome. Their analysis revealed that the prevalence of these RASs differed depending on the specific DAA regimen used, with elbasvir/grazoprevir and sofosbuvir/velpatasvir showing a higher frequency of NS5A RASs.

Understanding HCV Resistance to DAAs

The study sheds light on the complex mechanisms of HCV resistance to DAAs. The researchers identified specific viral mutations associated with treatment failure, providing valuable insights into the evolution of HCV resistance and informing future drug development efforts.

Health and Lifestyle Implications

The study's findings highlight the importance of monitoring for HCV resistance during DAA treatment. It's crucial for healthcare professionals to stay informed about emerging resistance patterns and adjust treatment strategies accordingly to ensure optimal treatment outcomes.

Dr. Camel's Conclusion

This study provides valuable insights into the complex world of HCV treatment and resistance. It emphasizes the importance of understanding the mechanisms of resistance and developing strategies to overcome these challenges. As a researcher, I am fascinated by the intricate interplay between viruses and antiviral therapies.
Date :
  1. Date Completed 2021-05-19
  2. Date Revised 2021-05-19
Further Info :

Pubmed ID

32599227

DOI: Digital Object Identifier

10.1016/j.ijantimicag.2020.106067

Related Literature

Article Analysis
・Effects of elbasvir and grazoprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.